USD $2361.44
JAKAVI is a prescription medication containing Ruxolitinib, a selective Janus kinase (JAK) inhibitor. It is primarily used in the treatment of certain types of blood disorders, including myelofibrosis and polycythemia vera. By targeting specific pathways in the immune system, JAKAVI helps to reduce inflammation and regulate the production of blood cells.
IndiaJAKAVI, containing the active ingredient Ruxolitinib, is a medication used for the treatment of certain conditions related to the immune system and blood disorders. It is primarily indicated for patients with myelofibrosis and polycythemia vera.
Ruxolitinib is a Janus kinase (JAK) inhibitor that works by blocking the activity of specific enzymes involved in the signaling pathways that contribute to the growth and activation of blood cells. This helps to reduce inflammation and control the symptoms associated with these conditions.
JAKAVI is typically taken orally, with or without food. Dosage is determined by a healthcare professional based on the patient's condition and response to treatment. It is important to follow the prescribed dosage and schedule.
Like all medications, JAKAVI may cause side effects. Common side effects include:
Patients should report any unusual symptoms or side effects to their healthcare provider promptly.
Before starting treatment with JAKAVI, inform your doctor about any existing medical conditions, particularly:
Regular monitoring may be required during treatment to ensure safety and effectiveness.
Store JAKAVI at room temperature, away from moisture and heat. Keep out of reach of children.
Always consult your healthcare provider for personalized advice and before starting any new medication, including JAKAVI.
